- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01174433
Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY) (SAFE-TRY)
연구 개요
상세 설명
Currently available stents were designed for straight lesions, optimised to provide scaffolding (coverage and radial strength) and ease of deliverability. In straight lesions, these stents have been shown to provide superb acute and long-term results. One lesion subset that continues to challenge the interventionalist is bifurcations lesions. A number of different strategies have been employed with standard stents to address bifurcation lesions each of which have significant limitations. Large contemporary registries characterising current stent usage in bifurcating lesions have demonstrated decreased procedural success with increased rates in restenosis and thrombosis (acute, subacute and delayed). The limitations of currently available stents have led groups to develop stents designed specifically to treat bifurcation lesions. The Tryton Side-Branch Stent Stent TM (Tryton Medical, Inc., Newton, MA, USA) is a balloon expandable cobalt chromium stent, designed specifically to treat bifurcation lesions.
The primary objective of this study is to evaluate the safety and feasibility of the use of the Tryton bifurcation coronary stent system for the treatment of single de novo bifurcation lesions in native coronary arteries with reference vessel diameters (RVD) for the proximal main vessel of 2.5 - 5.0 mm, distal main branch of 2.5 - 5.0 mm, and side branch RVD 2.5 - 3.5 mm.
연구 유형
등록 (실제)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Castelfranco Veneto, 이탈리아, 31033
- Castelfranco Veneto's Hospital
-
Conegliano, 이탈리아, 31015
- Conegliano's Hospital
-
Mestre, 이탈리아, 30170
- Angel's Hospital
-
Mirano, 이탈리아, 30035
- Mirano's Hospital
-
Padua, 이탈리아, 35128
- Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Italy
-
Vicenza, 이탈리아, 36100
- Vicenza's Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
General Inclusion Criteria
- Candidate for percutaneous coronary intervention & emergent coronary artery bypass graft surgery
- Clinical evidence of ischemic heart disease or a positive functional study
- Female patients of childbearing potential has negative pregnancy test within 7 days before trial procedure
- Patient or patient's legal representative provided written informed consent
- Patient agrees to comply with follow-up evaluations
Angiographic Inclusion Criteria
- Target lesion in a single de novo true bifurcation lesion (Medina classification Type 1.1.1; 1.0.1; 0.1.1; 0.0.1) involving a native coronary artery with reference vessel diameter for the proximal main of 2.5 - 5.0 mm, distal main of 2.5 - 5.0 mm, & side branch RVD of 2.5 - 3.5 mm
- Target lesion in main vessel has stenosis of > 50% and <100%
- Syntax score < 32
Exclusion Criteria:
General Exclusion Criteria
- Known hypersensitivity/contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, chromium, molybdenum, or sensitivity to contrast media, which can't be adequately pre-medicated
- Platelet count <100,000 cells/mm³ or >700,000 cells/mm³, or a white blood cell (WBC) count <3,000 cells/mm³ within 7 days prior to index procedure
- Serum creatinine level >170 micromol/L within 7 days prior to index procedure
- Evidence of acute MI within 72 hours of intended trial procedure (defined as: QWMI or NQWMI having CK enzymes >2X laboratory upper limit of normal in the presence of a confirming cardiac specific biomarker (Troponin I or T)
- Previous stenting anywhere in target vessel
- Percutaneous coronary intervention (PCI) of non-target vessel within 30 days prior to procedure that results in any MAC(C)E event. If non target vessel stent is implanted within 72 hours prior to index procedure, 2 post procedural serial CK or CK-MB measurements must be below investigational site's upper limit of normal
- PCI of non-target vessel within 24 hours prior to procedure
- Planned PCI of the target vessel within 6 months post-procedure
- During index procedure, target lesion requires treatment with device other than PTCA or cutting balloon prior to stent placement
- Documented left ventricular ejection fraction (LVEF) <30% at most recent evaluation
- History of stroke or transient ischemic attack (TIA) within prior 6 months
- Active peptic ulcer or upper gastrointestinal (GI) bleeding within prior 6 months
- History of bleeding diathesis or coagulopathy or will refuse blood transfusions
- Concurrent medical condition with life expectancy <12 months
- Currently participating in investigational drug or device trial that's not completed the primary endpoint or that clinically interferes with current trial endpoints; or requires coronary angiography, IVUS or other coronary artery imaging procedures.
Angiographic Exclusion Criteria
- Target lesion located in native vessel with saphenous vein graft or left/right internal mammary artery (LIMA/RIMA) bypass
- Target lesion has any of following characteristics:
- Severely calcified
- Evidence of thrombus
- Syntax score ≥33
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Tryton bifurcation stent system
|
Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
A composite of cardiac death, target vessel myocardial infarction (MI) and clinically driven target lesion revascularization (TLR) at 30 days post procedure
기간: 30 days (plus or minus 3 days)
|
A composite of cardiac death, target vessel myocardial infarction (MI) and clinically driven target lesion revascularization (TLR) at 30 days post procedure.
|
30 days (plus or minus 3 days)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Angiographic and Procedural success
기간: 30 days (plus or minus 3 days)
|
Acute device success, Technical Success, Clinical Procedural Success, Device malfunctions, Ease-of-Use parameters, Main branch and side branch angiographic endpoints, Main branch and side branch IVUS endpoints (Reference Lumen Area; Reference EEM Area; Lesion Lumen Area; Lesion EEM Area; Maximum Atheroma Thickness; Minimum Atheroma Thickness; Lesion Maximum Lumen Diameter; Lesion Minimum Lumen Diameter and derived Measurements; calcium measurement)
|
30 days (plus or minus 3 days)
|
Total volume of contrast used
기간: 24 hours
|
Total volume of contrast used, in mL
|
24 hours
|
Total index PCI procedure time
기간: 24 hours
|
Total index PCI procedure time, in minutes
|
24 hours
|
Target vessel revascularization (TVR) rate
기간: 9 months
|
Target vessel revascularization (TVR) rate, at 9 months
|
9 months
|
Target lesion revascularization (TLR) rate
기간: 9 months
|
Target lesion revascularization (TLR) rate, at 9 months
|
9 months
|
Major Adverse Cardiac and Cerebrovascular Events (MAC(C)E) rate
기간: 9 months
|
Major Adverse Cardiac and Cerebrovascular Events (MAC(C)E) rate, at 9 months
|
9 months
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Giuseppe Tarantini, MD, Ph.D., University of Padua, Department of Cardiac, Thoracic and Vascular Sciences
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 2040P
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
관상동맥 질환에 대한 임상 시험
-
Chinese Academy of Medical Sciences, Fuwai HospitalMedtronic; CCRF Consulting Co., Ltd.빼는Transradial-transfemoral Coronary Interventions 비교
-
CCRF Consulting Co., Ltd.Peking University First Hospital; Terumo Medical(shanghai) Co.,Ltd.알려지지 않은심장 또는 뇌혈관 질환 무료 요금 | Transradial-transfemoral Coronary Interventions 비교중국
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
-
Micell TechnologiesCardialysis BV; ClinLogix. LLC알려지지 않은
-
University Medical Center Groningen모병
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); US Department...완전한신장 질환 | 만성 신장 질환 | 급성 신부전 | 관상동맥(Artery); 질병
Tryton에 대한 임상 시험
-
Tryton Medical, Inc.완전한천연 관상 동맥의 관상 동맥 경화증 | 분기 병변: 천연 관상동맥의 주분지와 측분지의 드노보 병변미국